Deletion of Fifteen Open Reading Frames from Modified Vaccinia Virus Ankara Fails to Improve Immunogenicity

Modified vaccinia virus Ankara (MVA) is a highly attenuated strain of vaccinia virus, which has been used as a recombinant vaccine vector in many vaccine development programmes. The loss of many immunosuppressive and host-range genes resulted in a safe and immunogenic vaccine vector. However it still retains some immunomodulatory genes that may reduce MVA immunogenicity. Earlier reports demonstrated that the deletion of the A41L, B15R, C6L, or C12L open reading frames (ORFs) enhanced cellular immune responses in recombinant MVA (rMVA) by up to 2-fold. However, previously, we showed that deletion of the C12L, A44L, A46R, B7R, or B15R ORFs from rMVA, using MVA-BAC recombineering technology, did not enhance rMVA immunogenicity at either peak or memory cellular immune responses. Here, we extend our previous study to examine the effect of deleting clusters of genes on rMVA cellular immunogenicity. Two clusters of fifteen genes were deleted in one rMVA mutant that encodes either the 85A antigen of Mycobacterium tuberculosis or an immunodominant H2-Kd-restricted murine malaria epitope (pb9). The deletion mutants were tested in prime only or prime and boost vaccination regimens. The responses showed no improved peak or memory CD8+ T cell frequencies. Our results suggest that the reported small increases in MVA deletion mutants could not be replicated with different antigens, or epitopes. Therefore, the gene deletion strategy may not be taken as a generic approach for improving the immunogenicity of MVA-based vaccines, and should be carefully assessed for every individual recombinant antigen.

[1]  James M. Wilson,et al.  Single-Dose Protection against Plasmodium berghei by a Simian Adenovirus Vector Using a Human Cytomegalovirus Promoter Containing Intron A , 2008, Journal of Virology.

[2]  T. Pollard,et al.  Vaccinia virus expresses a novel profilin with a higher affinity for polyphosphoinositides than actin. , 1994, Biochemistry.

[3]  I. Haga,et al.  Vaccinia virus protein A46R targets multiple Toll-like–interleukin-1 receptor adaptors and contributes to virulence , 2005, The Journal of experimental medicine.

[4]  D. Stuart,et al.  Functional and structural studies of the vaccinia virus virulence factor N1 reveal a Bcl-2-like anti-apoptotic protein , 2007, The Journal of general virology.

[5]  M. Brown,et al.  Innate immune recognition of poxviral vaccine vectors , 2011, Expert review of vaccines.

[6]  C. Sorzano,et al.  Improving Adaptive and Memory Immune Responses of an HIV/AIDS Vaccine Candidate MVA-B by Deletion of Vaccinia Virus Genes (C6L and K7R) Blocking Interferon Signaling Pathways , 2013, PloS one.

[7]  D. Tscharke,et al.  The vaccinia virus B9R protein is a 6 kDa intracellular protein that is non-essential for virus replication and virulence. , 2002, The Journal of general virology.

[8]  D. Tscharke,et al.  The Vaccinia Virus Superoxide Dismutase-Like Protein (A45R) Is a Virion Component That Is Nonessential for Virus Replication , 2001, Journal of Virology.

[9]  N. Letvin,et al.  Kinetics of Recombinant Adenovirus Type 5, Vaccinia Virus, Modified Vaccinia Ankara Virus, and DNA Antigen Expression In Vivo and the Induction of Memory T-Lymphocyte Responses , 2008, Clinical and Vaccine Immunology.

[10]  G. Pantaleo,et al.  Deletion of the Viral Anti-Apoptotic Gene F1L in the HIV/AIDS Vaccine Candidate MVA-C Enhances Immune Responses against HIV-1 Antigens , 2012, PloS one.

[11]  H. Stickl,et al.  [The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl)]. , 1978, Zentralblatt fur Bakteriologie, Parasitenkunde, Infektionskrankheiten und Hygiene. Erste Abteilung Originale. Reihe B: Hygiene, Betriebshygiene, praventive Medizin.

[12]  G. Sutter,et al.  Modified Vaccinia virus Ankara: innate immune activation and induction of cellular signalling. , 2013, Vaccine.

[13]  D. Tscharke,et al.  A study of the vaccinia virus interferon-gamma receptor and its contribution to virus virulence. , 2002, The Journal of general virology.

[14]  J. Altman,et al.  Deletion of Specific Immune-Modulatory Genes from Modified Vaccinia Virus Ankara-Based HIV Vaccines Engenders Improved Immunogenicity in Rhesus Macaques , 2012, Journal of Virology.

[15]  C. Sorzano,et al.  Deletion of the Vaccinia Virus N2L Gene Encoding an Inhibitor of IRF3 Improves the Immunogenicity of Modified Vaccinia Virus Ankara Expressing HIV-1 Antigens , 2014, Journal of Virology.

[16]  M. Esteban,et al.  Improving the MVA Vaccine Potential by Deleting the Viral Gene Coding for the IL-18 Binding Protein , 2012, PloS one.

[17]  S. Lockhart,et al.  Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial , 2013, The Lancet.

[18]  G. Smith,et al.  A vaccinia serine protease inhibitor which prevents virus-induced cell fusion. , 1992, The Journal of general virology.

[19]  C. Staib,et al.  Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery. , 2003, Current drug targets. Infectious disorders.

[20]  R. L. Roper,et al.  Deletion of the A35 gene from Modified Vaccinia Virus Ankara increases immunogenicity and isotype switching. , 2011, Vaccine.

[21]  A. Hill,et al.  Long-Term Thermostabilization of Live Poxviral and Adenoviral Vaccine Vectors at Supraphysiological Temperatures in Carbohydrate Glass , 2010, Science Translational Medicine.

[22]  Nancy A. Jenkins,et al.  Simple and highly efficient BAC recombineering using galK selection , 2005, Nucleic acids research.

[23]  C. Sorzano,et al.  Immunogenic Profiling in Mice of a HIV/AIDS Vaccine Candidate (MVA-B) Expressing Four HIV-1 Antigens and Potentiation by Specific Gene Deletions , 2010, PloS one.

[24]  G. Smith,et al.  Vaccinia virus gene SalF5R is non-essential for virus replication in vitro and in vivo. , 1992, The Journal of general virology.

[25]  C. Staib,et al.  Transient host range selection for genetic engineering of modified vaccinia virus Ankara. , 2000, BioTechniques.

[26]  D. Webster,et al.  Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis. , 2006, Vaccine.

[27]  C. Sorzano,et al.  A Candidate HIV/AIDS Vaccine (MVA-B) Lacking Vaccinia Virus Gene C6L Enhances Memory HIV-1-Specific T-Cell Responses , 2011, PloS one.

[28]  H. Schäfer,et al.  MVA-Stufenimpfung gegen Pocken , 1974 .

[29]  A. Bowie,et al.  Vaccinia Virus Protein C6 Is a Virulence Factor that Binds TBK-1 Adaptor Proteins and Inhibits Activation of IRF3 and IRF7 , 2011, PLoS pathogens.

[30]  F. Falkner,et al.  The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. , 1998, Virology.

[31]  D. Spehner,et al.  Detection of a protein encoded by the vaccinia virus C7L open reading frame and study of its effect on virus multiplication in different cell lines. , 1993, The Journal of general virology.

[32]  H. Baker,et al.  Roles of Vaccinia Virus Genes E3L and K3L and Host Genes PKR and RNase L during Intratracheal Infection of C57BL/6 Mice , 2010, Journal of Virology.

[33]  B. Moss,et al.  Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. , 1997, Virology.

[34]  A. Hill,et al.  Recombination-Mediated Genetic Engineering of a Bacterial Artificial Chromosome Clone of Modified Vaccinia virus Ankara (MVA) , 2008, PloS one.

[35]  T. Peto,et al.  Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers. , 2003, Vaccine.

[36]  Margarida Saraiva,et al.  A chemokine-binding domain in the tumor necrosis factor receptor from variola (smallpox) virus. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[37]  H. Stickl,et al.  The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behaviour in organisms with a debilitated defence mechanism. , 1978 .

[38]  P. Romero,et al.  Isolation and characterization of protective cytolytic T cells in a rodent malaria model system. , 1990, Immunology letters.

[39]  A. Mayr,et al.  [MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's transl)]. , 1974, Deutsche medizinische Wochenschrift.

[40]  D. Tscharke,et al.  Deletion of gene A41L enhances vaccinia virus immunogenicity and vaccine efficacy. , 2006, The Journal of general virology.

[41]  S. Hornemann,et al.  Replication of Modified Vaccinia Virus Ankara in Primary Chicken Embryo Fibroblasts Requires Expression of the Interferon Resistance Gene E3L , 2003, Journal of Virology.

[42]  Geoffrey L. Smith,et al.  Steroid Hormone Synthesis by Vaccinia Virus Suppresses the Inflammatory Response to Infection , 2003, The Journal of experimental medicine.

[43]  H. Ren,et al.  Vaccinia virus protein N2 is a nuclear IRF3 inhibitor that promotes virulence , 2013, The Journal of general virology.

[44]  Geoffrey L. Smith,et al.  Vaccinia Virus Interleukin-18-Binding Protein Promotes Virulence by Reducing Gamma Interferon Production and Natural Killer and T-Cell Activity , 2003, Journal of Virology.

[45]  D. Tscharke,et al.  A study of the vaccinia virus interferon-γ receptor and its contribution to virus virulence , 2002 .

[46]  M. Esteban,et al.  Cellular and Biochemical Differences between Two Attenuated Poxvirus Vaccine Candidates (MVA and NYVAC) and Role of the C7L Gene , 2006, Journal of Virology.

[47]  B. Moss,et al.  Vaccinia virus A43R gene encodes an orthopoxvirus-specific late non-virion type-1 membrane protein that is dispensable for replication but enhances intradermal lesion formation. , 2010, Virology.

[48]  M. Esteban,et al.  Clinical applications of attenuated MVA poxvirus strain , 2013, Expert review of vaccines.

[49]  C. Staib,et al.  Inactivation of the viral interleukin 1beta receptor improves CD8+ T-cell memory responses elicited upon immunization with modified vaccinia virus Ankara. , 2005, The Journal of general virology.

[50]  J. Ramírez,et al.  Biology of Attenuated Modified Vaccinia Virus Ankara Recombinant Vector in Mice: Virus Fate and Activation of B- and T-Cell Immune Responses in Comparison with the Western Reserve Strain and Advantages as a Vaccine , 2000, Journal of Virology.

[51]  A. Banham,et al.  Characterization of vaccinia virus gene B12R. , 1993, The Journal of general virology.

[52]  J. Heeney,et al.  Viruses as vaccine vectors for infectious diseases and cancer , 2010, Nature Reviews Microbiology.

[53]  I. Siemion,et al.  The immunosuppressive activity of peptide fragments of vaccinia virus C10L protein and a hypothesis on the role of this protein in the viral invasion , 2002, Peptides.

[54]  B. Moss,et al.  Cell proliferative response to vaccinia virus is mediated by VGF. , 1988, Virology.

[55]  B. Moss,et al.  Identification of the vaccinia virus gene encoding an 18-kilodalton subunit of RNA polymerase and demonstration of a 5' poly(A) leader on its early transcript , 1990, Journal of virology.